In the modern era of patient-centered drug development, the only way to translate biological and genomic discoveries into clinically meaningful therapies is through partnerships among academia, industry, and government. To ensure that the integrity of the research is beyond reproach, investigators who engage in such collaborations are expected to disclose relationships that could potentially have an influence on the results or interpretation of the research project.1,2 Herein, we examine several dimensions of conflicts of interest (COIs), describe the distinct entity of conflicting interests, and describe how they may affect clinical cancer research.
Rothenberg ML, Johnson DH. Conflict of Interest, Conflicting Interests, and Effective Collaboration Between Academia and Industry on Preclinical and Clinical Cancer Research. JAMA Oncol. Published online July 06, 2017. doi:10.1001/jamaoncol.2017.1822
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.